Axonics reports preliminary 4q23 and fiscal year 2023 revenue

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended december 31, 2023. “the continued strong performance of axonics reflects the physician community's preference and enthusiasm for our best-in-class incontinence products,” said raymond w. cohen, chief exec.
AXNX Ratings Summary
AXNX Quant Ranking